|
Real-time Estimate
Cboe BZX
01:29:57 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 5.670 USD | -2.58% |
|
-5.97% | -51.33% |
| 14/08 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 14/08 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 58Cr 50Cr 47Cr 43Cr 80Cr 5.47TCr 80Cr 552.82Cr 215.29Cr 2.8TCr 217.34Cr 212.6Cr 9.01TCr | P/E 2026 * |
-3.18x | P/E 2027 * | -6.93x |
|---|---|---|---|---|---|
| Enterprise Value | 58Cr 50Cr 47Cr 43Cr 80Cr 5.47TCr 80Cr 552.82Cr 215.29Cr 2.8TCr 217.34Cr 212.6Cr 9.01TCr | EV / Sales 2026 * |
4.38x | EV / Sales 2027 * | 2.96x |
| Free-Float |
83.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SPRY | Delayed | |
CBOE
| SPRY | Real-time |
Last Transcript : ARS Pharmaceuticals, Inc.
| 1 day | -2.58% | ||
| 1 week | -5.97% | ||
| Current month | -5.50% | ||
| 1 month | +3.85% | ||
| 3 months | -35.20% | ||
| 6 months | -36.08% | ||
| Current year | -51.33% |
| 1 week | 5.6 |  | 6.09 |
| 1 month | 5 | | 6.58 |
| Current year | 4.91 | | 13.15 |
| 1 year | 4.91 | | 13.15 |
| 3 years | 2.55 | | 18.9 |
| 5 years | 2.55 | | 18.9 |
| 10 years | 2.55 | | 18.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bell
CTO | Chief Tech/Sci/R&D Officer | - | 05/08/2015 |
Donn Casale
CEO | Chief Executive Officer | 53 | 07/07/2026 |
Kathleen Scott
DFI | Director of Finance/CFO | 57 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CHM | Chairman | 56 | 08/11/2022 |
Rajeev Dadoo
BRD | Director/Board Member | 55 | 01/08/2021 |
Saqib Islam
BRD | Director/Board Member | 56 | 01/07/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/07/26 | Free | Chief Executive Officer | 8,98,456 | 0.9048% | ||
| 24/06/26 | Free | Director | 30,000 | 0.0302% | ||
| 02/01/26 | Free | General Counsel | 2,40,000 | 0.2428% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.58% | -5.97% | -47.89% | -19.92% | 58Cr | |
| -0.24% | -1.09% | +2.00% | +17.50% | 5.01TCr | |
| +1.55% | -4.83% | +429.19% | +524.70% | 4.48TCr | |
| +2.96% | +2.96% | +46.33% | +22.30% | 4.34TCr | |
| +0.07% | -2.69% | +7.79% | +76.95% | 4.11TCr | |
| +0.43% | -3.26% | +14.75% | +49.08% | 3.29TCr | |
| +1.37% | +8.21% | - | - | 1.76TCr | |
| -0.18% | -3.24% | +22.97% | +123.23% | 1.66TCr | |
| +0.93% | +0.88% | +19.64% | +29.70% | 1.46TCr | |
| +0.40% | -1.19% | +80.43% | +43.37% | 1.39TCr | |
| Average | +0.35% | -1.04% | +63.91% | +96.32% | 2.76TCr | |
| Weighted average by Cap. | +0.73% | -1.13% | +92.67% | +128.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13Cr 11Cr 11Cr 9.77Cr 18Cr 1.25TCr 18Cr 126.35Cr 49Cr 639.04Cr 50Cr 49Cr 2.06TCr | 20Cr 17Cr 16Cr 14Cr 27Cr 1.85TCr 27Cr 186.93Cr 73Cr 945.46Cr 73Cr 72Cr 3.04TCr |
| Net income | -18Cr -16Cr -15Cr -13Cr -25Cr -1.72TCr -25Cr -173.77Cr -68Cr -878.88Cr -68Cr -67Cr -2.83TCr | -8.46Cr -7.28Cr -6.83Cr -6.25Cr -12Cr -800.14Cr -12Cr -81Cr -31Cr -408.9Cr -32Cr -31Cr -1.32TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | $5.670 | -2.58% | 7,28,679 |
| 02/26/02 | $5.820 | +0.87% | 11,96,978 |
| 01/26/01 | $5.770 | -3.83% | 13,58,006 |
| 31/26/31 | $6.000 | +1.87% | 19,84,647 |
| 28/26/28 | $5.890 | -2.32% | 11,90,271 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SPRY Stock
Select your edition
All financial news and data tailored to specific country editions
